Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 08:13 ET | Source: Yamo Pharmaceuticals

Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025

Yamo Pharma's Phase 2 data at INSAR 2025 show L1-79 delivers statistically significant and clinically meaningful improvements in core autism symptoms.
February 09, 2022 16:04 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo...
February 16, 2017 07:02 ET | Source: Neuralstem, Inc.

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development...
December 23, 2013 06:45 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Reports Results from Phase 2a Study of Intravenous Ion Channel Activator for Lumbar Spinal Stenosis

BETHESDA, Md., Dec. 23, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (Sucampo) today announced the results of its double-blind, placebo-controlled Phase 2a proof of concept...